RxDoctor Payments Data

Ramon Santiago, MD

Family Medicine · Tampa, FLNPI 1013923713

Payments from drug & device makers

$164,611in general payments, 2019–2025

Across 504 payments — averaging $326.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$151K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$829
  • Lilly USA, LLC$464
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,946100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,611 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$62,393
Medicare patients
148
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$57,799
FarxigaDapagliflozin Propanediol62$56,155
EliquisApixaban37$36,602
JanuviaSitagliptin Phosphate22$35,806
JardianceEmpagliflozin40$29,638
XareltoRivaroxaban21$18,432
Atrovent HfaIpratropium Bromide15$6,856
Atorvastatin Calcium409$3,376
Omega-3 Acid Ethyl Esters26$2,186
Omeprazole75$1,651
Nebivolol Hcl16$1,613
Silodosin12$1,289
ValacyclovirValacyclovir Hcl13$1,230
Alprazolam222$1,225
Lisinopril186$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,065$57,79944 claims
AstraZenecaFarxiga$2,024$56,15562 claims
PfizerEliquis$293$36,60237 claims
MerckJanuvia$277$35,80622 claims
Boehringer IngelheimJardiance$179$29,63840 claims
Johnson & JohnsonXarelto$182$18,43221 claims
AbbVieSynthroid$829$1,08324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →